Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

4 terminated/withdrawn out of 44 trials

Success Rate

84.0%

-2.5% vs industry average

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

0%

0 of 21 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 2
14(77.8%)
Phase 3
3(16.7%)
N/A
1(5.6%)
18Total
Phase 2(14)
Phase 3(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT04158258Active Not Recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Role: collaborator

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT06068985Phase 2Active Not Recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Role: lead

NCT03942497Completed

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Role: lead

NCT04558866Phase 2Active Not Recruiting

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

Role: lead

NCT05299125Phase 2Active Not Recruiting

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Role: lead

NCT06527690Phase 2Withdrawn

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Role: lead

NCT06822543Phase 2Recruiting

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

Role: lead

NCT07192991Not Yet Recruiting

Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

Role: lead

NCT02194842Phase 3Active Not Recruiting

Phase III Radium 223 mCRPC-PEACE III

Role: collaborator

NCT05776147Recruiting

Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Role: lead

NCT05328765Recruiting

A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

Role: lead

NCT06014580Active Not Recruiting

Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil

Role: lead

NCT04943445Phase 2Active Not Recruiting

Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

Role: lead

NCT05857397Active Not Recruiting

A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

Role: lead

NCT05184504Completed

Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

Role: lead

NCT05168631Active Not Recruiting

Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors

Role: lead

NCT05924789Completed

Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

Role: lead

NCT06279442Recruiting

Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort

Role: lead

NCT04962919Active Not Recruiting

Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Role: lead